# Sickle Cell Anemia

Sickle cell anemia requires longitudinal, multidisciplinary care focused on preventing stroke and infection, modifying disease severity, safely managing acute complications, and evaluating curative cellular therapies for appropriately selected patients.

**Clinical question:** How should physicians organize prevention, disease modification, complication management, and curative-therapy referral for patients with sickle cell anemia?

Updated: 2026-08-21T00:43:14.402180+00:00

## What matters in practice
- Sickle cell anemia is caused by HbS polymerization during deoxygenation, producing hemolysis, vaso-occlusion, chronic anemia, inflammation, vasculopathy, and progressive multiorgan injury. [18]
- Care should be coordinated with a sickle cell disease specialist; primary care is central to preventive care, recognition of complications, and management of non-SCD comorbidity. [18]
- Children with sickle cell anemia should receive penicillin prophylaxis through age 5 years and annual transcranial Doppler screening from ages 2 through 16 years. [3]
- Transfusion decisions should be individualized and guided by established SCD transfusion-support recommendations because recurrent transfusion creates risks including iron overload and transfusion-related complications. [4][20]
- FDA-approved autologous cellular gene therapies offer a potentially disease-modifying option for selected patients aged 12 years or older with SCD and vaso-occlusive events, but require intensive transplant-style evaluation and follow-up. [9][14]

## Priorities in longitudinal care

Management should anticipate complications rather than respond only to pain episodes.

Sickle cell anemia is the severe HbSS phenotype within sickle cell disease. Deoxygenated HbS polymerization drives red-cell deformation and initiates vaso-occlusion, hemolysis, chronic anemia, endothelial dysfunction, inflammation, oxidative stress, and cumulative organ injury. [18] This mechanism explains why an apparently routine presentation—pain, fever, anemia, hypoxemia, neurologic symptoms, or jaundice—may signal an evolving organ-threatening complication.

A medical-home model linking hematology, primary care, emergency care, pain management, obstetrics when relevant, and organ-specific specialists is clinically important. Adults remain substantially disadvantaged in survival, with life expectancy reported as more than two decades shorter than that of the general population; disease complications increasingly interact with age-related cardiovascular, renal, hepatic, and other comorbidities. [18]
- Confirm the patient’s genotype, baseline hemoglobin and hemolysis profile, historical frequency and phenotype of vaso-occlusive events, transfusion exposure, alloantibody history, disease-modifying treatment history, and organ complications before interpreting an acute change.
- Treat new focal neurologic findings, chest symptoms or hypoxemia, rapidly worsening anemia, fever, or progressive jaundice as potential SCD emergencies requiring prompt diagnostic evaluation and specialist involvement. The supplied sources support these complications as clinically important but do not provide validated emergency diagnostic pathways or treatment thresholds. [13][18][20]
- Review reproductive goals and pregnancy plans early; pregnancy care should involve clinicians experienced in SCD, hematology, obstetrics, and neonatal care. [19][24]

## Establish phenotype and complication burden

Genotype alone does not define current risk or treatment needs.

Sickle cell disease results from inherited abnormalities involving the beta-globin gene; in sickle cell anemia, HbS arises from substitution of valine for glutamic acid at the sixth beta-globin codon. [8][18] Clinical severity varies across SCD genotypes, and HbSS is generally the most severe phenotype. [20][21]

At transition to a new clinician or care system, establish the individual baseline against which acute changes will be judged. The available sources support comprehensive complication surveillance but do not provide a sufficiently detailed, source-supported laboratory panel, surveillance interval set, or diagnostic threshold schedule to specify beyond specialty-guided care. [4][17][18]
- Document hemoglobin genotype and prior confirmatory testing; distinguish sickle cell anemia from HbSC disease and HbS beta-thalassemia because complication profiles and transfusion needs may differ. [20]
- Record baseline anemia, pain-event history, acute chest syndrome, stroke or transient neurologic events, renal and hepatic disease, gallstone disease, priapism, pregnancy history, and transfusion complications.
- Obtain and prominently preserve transfusion records, including red-cell antibodies and prior delayed hemolytic reactions, before elective transfusion planning. Transfusion support is addressed in dedicated ASH guidance. [4][19]

*Baseline domains that alter subsequent SCD decisions. [4][17][18][20]*

| Domain | Why it changes management |
| --- | --- |
| Neurologic history and prior screening | Identifies patients with established cerebrovascular disease or need for pediatric stroke-prevention surveillance. [3][4] |
| Transfusion and antibody history | Guides transfusion planning and helps mitigate transfusion-related complications; recurrent transfusion can contribute to iron overload. [4][20] |
| Hepatobiliary status | Liver disease may reflect intrahepatic sickling, transfusional iron overload, viral hepatitis, gallstone-related obstruction, or unrelated liver disease. [20] |
| Pregnancy plans or pregnancy | Requires early multidisciplinary planning because SCD complicates maternal and fetal care. [19][24] |

## Prevent infection and childhood stroke

Pediatric prevention measures remain among the highest-value SCD interventions.

The supplied evidence summarizes longstanding guideline-based pediatric prevention measures: penicillin prophylaxis for children through age 5 years and annual transcranial Doppler examination from ages 2 through 16 years. [3] These measures should be embedded in a comprehensive SCD program rather than treated as isolated primary-care tasks.

The search results identify ASH and NHLBI clinical guidance as core U.S. resources for SCD management and describe CDC tools intended to support implementation. [17] Specific vaccine schedules, Doppler velocity thresholds, and downstream transfusion protocols are not provided in the supplied results and should be verified in the current guideline and local hematology pathway.
- Penicillin prophylaxis: 125 mg orally twice daily for children younger than 3 years, then 250 mg orally twice daily through age 5 years. [3]
- Transcranial Doppler: perform annually in children aged 2 to 16 years. [3]
- Use dedicated SCD guidance for cerebrovascular prevention, diagnosis, and treatment in children and adults. [4][17]
- Ensure routine preventive care and age-appropriate vaccination are coordinated through primary care and hematology; the supplied sources do not provide vaccine product or interval details. [17][18]

## Disease modification and medication selection

Hydroxyurea remains foundational, while selection of newer agents requires current-label and specialist review.

Hydroxyurea increases fetal hemoglobin production and has been a central disease-modifying therapy for sickle cell anemia. [8][15] The supplied evidence notes benefit in young children and identifies hydroxyurea among expert-panel treatment recommendations. [3] However, it does not provide source-supported U.S. initiation doses, titration schedules, laboratory targets, contraindications, or monitoring intervals; these should be taken from current FDA labeling and contemporary hematology guidance rather than inferred.

Therapeutic development has expanded beyond hydroxyurea, including anti-sickling approaches and cellular therapies. [23] Voxelotor demonstrated dose-dependent increases in hemoglobin–oxygen affinity in early clinical development and was evaluated in a phase 3 trial. [6] The supplied results do not establish its current U.S. regulatory status, indication, dose, safety restrictions, or role after later safety and market changes; do not prescribe from this evidence summary alone.
- Consider hydroxyurea within a hematology-supervised disease-modifying plan for patients with sickle cell anemia; use current prescribing information for dose selection and monitoring. [3][8][15]
- Do not extrapolate drug doses, treatment targets, or comparative efficacy among newer agents from the supplied search results.
- Review adherence barriers, reproductive planning, prior response, toxicity history, transfusion burden, and access to specialty care when revisiting disease-modifying therapy.

*Therapeutic evidence represented in the supplied sources.*

| Approach | Supported clinical implication | Important limitation |
| --- | --- | --- |
| Hydroxyurea | Enhances fetal hemoglobin production and is included in expert recommendations for SCD management. [3][8] | No source-supported dose, titration, monitoring, or contraindication details are available in the supplied results. |
| Voxelotor | Phase 1/2 data showed dose-dependent increases in hemoglobin–oxygen affinity, and a phase 3 trial was reported. [6] | Current U.S. availability and prescribing role are not established by the supplied results. |
| Autologous gene therapy | FDA approved cellular gene therapies for SCD, including treatment of eligible patients with vaso-occlusive events. [9][14] | Requires conditioning, stem-cell collection and reinfusion, specialized-center care, and long-term follow-up; detailed selection criteria are not supplied. [9] |

## Escalate evaluation for organ-threatening presentations

Pain may be familiar; the accompanying physiology determines urgency.

Vaso-occlusion causes severe pain and can lead to organ damage, while hemolysis contributes to chronic anemia. [8][9][18] Acute care should therefore assess for complications rather than assuming uncomplicated vaso-occlusive pain. The supplied sources identify analgesia, hydration, transfusion for severe anemia, antibiotic treatment or prevention when infection is relevant, and comprehensive care as components of symptomatic management, but do not provide an evidence-supported acute treatment algorithm or dosing regimen. [13]

SCD-associated liver disease has a broad differential. Hepatic injury can arise from intrahepatic sickling and hypoxic injury, transfusion-associated iron overload or viral hepatitis, gallstone-related biliary obstruction, or coincidental hepatic disease. [20] Acute or chronic cholestatic presentations should therefore not be attributed reflexively to hemolysis without evaluating hepatobiliary and transfusion-related causes.
- In acute pain, evaluate for fever, hypoxemia, respiratory symptoms, neurologic symptoms, acute anemia, and abdominal or hepatic findings that may indicate a complication requiring escalation.
- For suspected hepatic complications, consider sickling-related injury, biliary obstruction, transfusion-associated iron overload, viral hepatitis, and non-SCD liver disease in the diagnostic framework. [20]
- Use transfusion support through clinicians experienced in SCD, particularly when a patient has prior antibodies, transfusion reactions, iron burden, or a potential indication for exchange transfusion. [4][19][20]
- Use individualized pain plans and current SCD pain guidance; the CDC identifies dedicated resources for acute and chronic SCD pain management. [17]

## Transfusion support and referral for potentially curative therapy

Transfusion and cellular therapy decisions require specialized risk assessment.

Red-cell transfusion remains an important component of SCD care, including support for severe anemia and selected complications. [13] Its use must balance clinical benefit against alloimmunization, hemolytic transfusion reactions, iron overload, and infectious risks. ASH published transfusion-support guidance, and patients with complex transfusion histories should be managed with hematology and transfusion medicine input. [4][19][20]

The FDA approved exagamglogene autotemcel (Casgevy) and lovotibeglogene autotemcel (Lyfgenia) as the first gene therapies for SCD. [9][14] Lyfgenia is approved for patients aged 12 years or older with SCD and a history of vaso-occlusive events; it uses autologous hematopoietic stem cells modified with a lentiviral vector to produce HbAT87Q, a hemoglobin designed to reduce red-cell sickling. [9] Casgevy uses CRISPR/Cas9 editing of autologous hematopoietic stem cells to increase fetal hemoglobin production after reinfusion and engraftment. [9]

Referral is appropriate when recurrent vaso-occlusive morbidity persists despite optimized conventional care, when transfusion burden or progressive organ injury is substantial, or when the patient seeks evaluation for cellular therapy. Eligibility, conditioning suitability, fertility implications, access, and long-term safety surveillance must be addressed at a specialized transplant or gene-therapy center. The supplied sources do not provide sufficient detail to specify comparative efficacy, conditioning regimens, or patient-level contraindications. [9][14][17]
- Before elective transfusion, verify genotype, indication, prior red-cell antibodies, prior transfusion reactions, and cumulative transfusion exposure.
- Refer patients considering gene therapy for formal evaluation rather than representing treatment as a low-intensity outpatient intervention. Both described products involve autologous stem-cell collection, modification, and reinfusion. [9]
- Discuss uncertainty explicitly: current sources establish FDA approval and biologic rationale but do not provide long-term comparative outcomes, durability estimates, or detailed safety-monitoring requirements. [9][14]

*FDA-approved gene-therapy approaches described in the supplied results. [9][14]*

| Product | Platform and intended biologic effect | Population described in supplied source |
| --- | --- | --- |
| Lyfgenia (lovotibeglogene autotemcel) | Lentiviral modification of autologous hematopoietic stem cells to produce HbAT87Q, which functions similarly to HbA and is intended to reduce sickling. [9] | Patients aged 12 years or older with SCD and a history of vaso-occlusive events. [9] |
| Casgevy (exagamglogene autotemcel) | CRISPR/Cas9-edited autologous hematopoietic stem cells designed to increase fetal hemoglobin production after engraftment. [9] | FDA approval is reported, but the supplied excerpt does not provide a complete labeled population. [9][14] |

## Pregnancy and adult transition require proactive planning

Pregnancy and transfer from pediatric to adult care are predictable points of increased vulnerability.

Pregnant patients with SCD should receive individualized multidisciplinary care involving clinicians with relevant expertise, including hematology, obstetrics, midwifery, pediatrics, and neonatal care as appropriate. [19][24] WHO emphasizes preconception or early-pregnancy discussion of treatment choices and plans for anticipated complications. [24] For U.S. practice, consult current maternal-fetal medicine and hematology guidance for medication, transfusion, fetal surveillance, and delivery decisions because those details are not supplied here.

Adult transition should preserve the preventive and disease-modifying infrastructure established in childhood. Primary care clinicians are particularly important in maintaining health maintenance, coordinating specialty services, addressing comorbidities, and avoiding fragmentation that can worsen acute-care reliance. [18]
- Address contraception, reproductive goals, fertility preservation considerations, and pregnancy planning before treatment changes whenever possible.
- Ensure that a transition plan includes an identified adult hematology team, a transfusion record, an individualized pain plan, and medication reconciliation.
- Do not apply general-population pregnancy or opioid approaches without accounting for SCD-specific risks and care coordination needs. [19][24]

## Common questions

### Which children with sickle cell anemia need transcranial Doppler screening?

The supplied expert-summary source recommends annual transcranial Doppler examinations for children aged 2 through 16 years. Obtain the current ASH cerebrovascular guideline for velocity thresholds and management of abnormal results. [3][4]

### What penicillin prophylaxis regimen is supported for young children with sickle cell anemia?

The supplied source recommends penicillin 125 mg orally twice daily for children younger than 3 years, then 250 mg orally twice daily through age 5 years. [3]

### When should a patient be referred for gene-therapy evaluation?

Refer patients with substantial vaso-occlusive morbidity, progressive disease burden, or interest in potentially curative therapy to a specialized cellular-therapy center. FDA-approved options include Casgevy and Lyfgenia; Lyfgenia is described for patients aged 12 years or older with prior vaso-occlusive events. [9][14]

### Why is liver disease in sickle cell anemia diagnostically complex?

Hepatic abnormalities may reflect intrahepatic sickling and hypoxic injury, transfusional iron overload, viral hepatitis, gallstone-related obstruction, or unrelated liver disease. A broad diagnostic approach is needed rather than assuming hemolysis alone. [20]

## References
1. - IIER - accessdata.fda.gov — www.accessdata.fda.gov — https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219962Orig1s000Lbl.pdf
2. A novel US-based grading system for disease severity in ... — www.thelancet.com — https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00076-1/abstract
3. Managing Sickle Cell Disease: An Update | NEJM Clinician — clinician.nejm.org — https://clinician.nejm.org/managing-sickle-cell-disease-update-nejm-jw.NA35653
4. Sickle cell anemia - Symptoms, diagnosis and treatment | BMJ Best Practice US — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-us/100
5. Gene Therapy — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMra1706910
6. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell ... — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMoa1903212
7. A Proactive Response to Prescription Opioid Abuse — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMsr1601307
8. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia — www.nejm.org — https://www.nejm.org/doi/full/10.1056/NEJMoa2031054
9. FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease | FDA — go.nature.com — https://go.nature.com/4gmaHL3
10. A More Accurate Method To Estimate Glomerular Filtration ... — annals.org — https://annals.org/article.aspx?doi=10.7326%2F0003-4819-130-6-199903160-00002
11. Oral health management considerations for patients with sickle cell disease - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0011502917302067
12. New WHO recommendations on the management of sickle ... — obgyn.onlinelibrary.wiley.com — https://obgyn.onlinelibrary.wiley.com/doi/full/10.1002/pmf2.70069
13. CRISPR/Cas9 in the treatment of sickle cell disease (SCD)... : Annals of Medicine and Surgery — journals.lww.com — https://journals.lww.com/annals-of-medicine-and-surgery/fulltext/2024/10000/crispr_cas9_in_the_treatment_of_sickle_cell.37.aspx
14. Medication Update : The Nurse Practitioner — journals.lww.com — https://journals.lww.com/tnpj/fulltext/2024/02000/medication_update.12.aspx
15. Innovative Treatments for Rare Anemias : HemaSphere — journals.lww.com — https://journals.lww.com/hemasphere/fulltext/2021/06000/innovative_treatments_for_rare_anemias.7.aspx
16. Abstracts at CIDSCON 2024 : Journal of Clinical Infectious ... — journals.lww.com — https://journals.lww.com/cids/fulltext/2024/02030/abstracts_at_cidscon_2024.13.aspx
17. Sickle Cell Information for Healthcare Providers | Sickle Cell Disease (SCD) | CDC — www.cdc.gov — https://www.cdc.gov/sickle-cell/hcp/information
18. [PDF] Sickle cell disease: A primary care update — www.ccjm.org — https://www.ccjm.org/content/ccjom/87/1/19.full.pdf
19. Society for Maternal-Fetal Medicine Consult Series #68: Sickle cell disease in pregnancy — www.ajog.org — https://www.ajog.org/article/S0002-9378%2823%2900767-6/fulltext
20. Management of liver complications in sickle cell disease — ashpublications.org — https://ashpublications.org/hematology/article/2019/1/345/422572/Management-of-liver-complications-in-sickle-cell
21. Data and Statistics on Sickle Cell Disease | Sickle Cell Disease (SCD) | CDC — www.cdc.gov — https://www.cdc.gov/sickle-cell/data?CDC_AAref_Val=https%3A%2F%2Fwww.cdc.gov%2Fncbddd%2Fsicklecell%2Fdata.html
22. WHO consolidated guidelines for the management of common childhood illness: management of sickle-cell disease in children and adolescents — www.who.int — https://www.who.int/publications/i/item/9789240122666
23. Recent Advances in the Treatment of Sickle Cell Disease - PubMed — www.ncbi.nlm.nih.gov — http://www.ncbi.nlm.nih.gov/pubmed/32508672
24. WHO issues first global guideline to improve pregnancy care for women with sickle cell disease — www.who.int — https://www.who.int/news/item/19-06-2025-who-issues-first-global-guideline-to-improve-pregnancy-care-for-women-with-sickle-cell-disease

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.